These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11312008)

  • 1. Long-term persistence of cellular immunity to Oka vaccine virus induced by pernasal co-administration with Escherichia coli enterotoxin in mice.
    Kamiya N; Asano Y; Yoshino J; Sasaki K; Honma Y; Kawase H; Yokochi T; Shiraki K; Tsuji T
    Vaccine; 2001 Apr; 19(23-24):3131-6. PubMed ID: 11312008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant action of Escherichia coli enterotoxin for delayed-type hypersensitivity to Oka vaccine virus on pernasal co-administration in mice.
    Sasaki K; Asano Y; Honma Y; Kamiya N; Handa T; Ichinose Y; Yokochi T; Shiraki K; Tsuji T
    Vaccine; 2000 Nov; 19(7-8):931-6. PubMed ID: 11115718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of cellular immunity to varicella-zoster virus glycoproteins tested with pernasal coadministration of Escherichia coli enterotoxin in mice.
    Tsuji T; Shiraki K; Sato H; Sasaki K; Arita M; Kato M; Takahashi T; Ochi S; Ichinose Y; Yokochi T; Asano Y
    J Med Virol; 2003 Mar; 69(3):451-8. PubMed ID: 12526058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice.
    Sasaki K; Kato M; Takahashi T; Ochi S; Ichinose Y; Shiraki K; Asano Y; Iwanaga M; Tsuji T
    J Med Virol; 2003 Jun; 70(2):329-35. PubMed ID: 12696126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral immunoresponse to varicella-zoster virus pernasally coadministered with Escherichia coli enterotoxin in mice.
    Tsuji T; Shiraki K; Sato H; Yue-Mea J; Honma Y; Yoshikawa T; Asano Y
    Vaccine; 2000 Apr; 18(19):2049-54. PubMed ID: 10706968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mutant of Escherichia coli enterotoxin inducing a specific Thl-type of T cells to varicella-zoster vaccine enhances the production of IL-12 by IFNgamma-stimulated macrophages.
    Shimizu T; Sasaki K; Kato M; Arimitsu H; Ochi S; Yano T; Oguma K; Yokochi T; Tsuji T
    Vaccine; 2006 May; 24(18):3719-26. PubMed ID: 16115702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
    Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein.
    Erume J; Partidos CD
    Afr Health Sci; 2011 Jun; 11(2):151-7. PubMed ID: 21857843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63).
    Pine S; Barackman J; Ott G; O'Hagan D
    J Control Release; 2002 Dec; 85(1-3):263-70. PubMed ID: 12480330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.
    Komase K; Tamura S; Matsuo K; Watanabe K; Hattori N; Odaka A; Suzuki Y; Kurata T; Aizawa C
    Vaccine; 1998; 16(2-3):248-54. PubMed ID: 9607038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
    Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
    Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal adjuvant properties of mutant LT-IIa and LT-IIb enterotoxins that exhibit altered ganglioside-binding activities.
    Nawar HF; Arce S; Russell MW; Connell TD
    Infect Immun; 2005 Mar; 73(3):1330-42. PubMed ID: 15731030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
    Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
    Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants.
    McCluskie MJ; Weeratna RD; Clements JD; Davis HL
    Vaccine; 2001 Jun; 19(27):3759-68. PubMed ID: 11395211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
    Byrd W; Boedeker EC
    Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity.
    Ryan EJ; McNeela E; Pizza M; Rappuoli R; O'Neill L; Mills KH
    J Immunol; 2000 Nov; 165(10):5750-9. PubMed ID: 11067933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2.
    Hazama M; Mayumi-Aono A; Miyazaki T; Hinuma S; Fujisawa Y
    Immunology; 1993 Apr; 78(4):643-9. PubMed ID: 8388365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.